iStent
DeviceGlaukos iStent, medication
Other names: stent, trabecular micro-bypass stent
NCT Number: NCT00911924
Prospective, unmasked, evaluation of the iStent in patients that have primary open-angle glaucoma (OAG). Stent implantation in one eye will be used for analysis, with medication added at 6 months, as required.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 4
S.V. Malayan's Ophtalmology Centre, Yerevan, Armenia
One hundred patients will be enrolled in the study at up to 21 sites; follow-up is through 1 year.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Glaukos iStent, medication
Other names: stent, trabecular micro-bypass stent
Time frame: At 6 months
Time frame: 12 months
Time frame: 12 months
Glaukos Corporation
Industry
Acronym: SY
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00913029
Eye Diseases, Glaucoma
Yerevan, Armenia
View Trial DetailsNCT02710916
Eye Diseases, Glaucoma
Bordeaux, Aquitaine, France
View Trial DetailsNCT05876689
Eye Diseases, Glaucoma
Palo Alto, California, United States
View Trial DetailsNCT06213896
Age-Related Macular Degeneration, Cardiovascular Diseases
Antalya, Turkey (Türkiye)
View Trial Details